ES2996892T3 - Use of riluzole prodrugs to treat ataxias - Google Patents

Use of riluzole prodrugs to treat ataxias Download PDF

Info

Publication number
ES2996892T3
ES2996892T3 ES18876779T ES18876779T ES2996892T3 ES 2996892 T3 ES2996892 T3 ES 2996892T3 ES 18876779 T ES18876779 T ES 18876779T ES 18876779 T ES18876779 T ES 18876779T ES 2996892 T3 ES2996892 T3 ES 2996892T3
Authority
ES
Spain
Prior art keywords
ataxia
patients
riluzole
patient
bhv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18876779T
Other languages
English (en)
Spanish (es)
Inventor
Vladimir Coric
Robert Berman
Melissa Beiner
Gilbert L'italien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2996892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Application granted granted Critical
Publication of ES2996892T3 publication Critical patent/ES2996892T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18876779T 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias Active ES2996892T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US201862717948P 2018-08-13 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Publications (1)

Publication Number Publication Date
ES2996892T3 true ES2996892T3 (en) 2025-02-13

Family

ID=66438598

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18876779T Active ES2996892T3 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Country Status (26)

Country Link
US (3) US20210023061A1 (cg-RX-API-DMAC7.html)
EP (4) EP4696324A3 (cg-RX-API-DMAC7.html)
JP (2) JP7352542B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200103658A (cg-RX-API-DMAC7.html)
CN (1) CN112292127A (cg-RX-API-DMAC7.html)
AU (1) AU2018364749C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020009173A2 (cg-RX-API-DMAC7.html)
CA (1) CA3082096A1 (cg-RX-API-DMAC7.html)
DK (2) DK3706739T3 (cg-RX-API-DMAC7.html)
ES (1) ES2996892T3 (cg-RX-API-DMAC7.html)
FI (2) FI3706739T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241675T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070302T2 (cg-RX-API-DMAC7.html)
IL (1) IL274532B2 (cg-RX-API-DMAC7.html)
LT (2) LT3706739T (cg-RX-API-DMAC7.html)
MD (2) MD3706739T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020004678A (cg-RX-API-DMAC7.html)
PH (1) PH12020550583A1 (cg-RX-API-DMAC7.html)
PL (2) PL3706739T3 (cg-RX-API-DMAC7.html)
PT (2) PT3706739T (cg-RX-API-DMAC7.html)
RS (2) RS67956B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202004332XA (cg-RX-API-DMAC7.html)
SI (2) SI3706739T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202500022T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019094851A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002626B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
DK3265448T3 (da) 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
EP4426702A1 (en) * 2021-11-04 2024-09-11 Skyhawk Therapeutics, Inc. Condensed-pyrazine amine derivatives for treating sca3
JP2025517509A (ja) * 2022-05-23 2025-06-05 バイオヘイブン・セラピューティクス・リミテッド 脊髄小脳失調症を治療する方法
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
ES2318869T3 (es) 1997-02-20 2009-05-01 Massachusetts Institute Of Technology Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion.
DK1001748T3 (da) 1997-07-25 2006-08-21 Alpex Pharma Sa Fremgangsmåde til fremstilling af et granulat, som er egnet til fremstilling af i munden oplöselige tabletter, som kan sönderdeles hurtigt
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
JP2005508939A (ja) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
WO2003068604A1 (en) 2002-02-13 2003-08-21 Weibel Michael K Drug dose-form and method of manufacture
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
EP2271344A4 (en) * 2008-03-31 2011-04-27 Univ South Florida METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf

Also Published As

Publication number Publication date
MX2023012640A (es) 2023-11-08
JP2021502392A (ja) 2021-01-28
EP3706739A4 (en) 2021-08-04
PH12020550583A1 (en) 2021-05-31
EP3706739B1 (en) 2024-10-16
EP4483956A2 (en) 2025-01-01
DK3706739T3 (da) 2024-12-02
MX2020004678A (es) 2020-08-13
AU2018364749C1 (en) 2024-02-15
HRP20260391T1 (hr) 2026-05-22
ZA202002626B (en) 2025-02-26
HUE070302T2 (hu) 2025-05-28
DK4483956T3 (da) 2026-03-23
FI4483956T3 (fi) 2026-03-16
MD3706739T2 (ro) 2025-02-28
EP4696324A3 (en) 2026-05-06
US12102618B2 (en) 2024-10-01
PL3706739T3 (pl) 2025-03-10
IL274532B1 (en) 2024-01-01
EP3706739A1 (en) 2020-09-16
EP4699619A2 (en) 2026-02-25
US20210023061A1 (en) 2021-01-28
SI4483956T1 (sl) 2026-06-30
HRP20241675T1 (hr) 2025-02-14
KR20200103658A (ko) 2020-09-02
MD4483956T2 (ro) 2026-06-30
US20230355592A1 (en) 2023-11-09
JP7352542B2 (ja) 2023-09-28
AU2018364749B2 (en) 2023-11-09
PT3706739T (pt) 2024-12-04
NZ765220A (en) 2023-11-24
JP2023175823A (ja) 2023-12-12
PL4483956T3 (pl) 2026-07-27
LT3706739T (lt) 2024-12-27
EP4483956B1 (en) 2025-12-31
IL274532B2 (en) 2024-05-01
WO2019094851A1 (en) 2019-05-16
RS66277B1 (sr) 2025-01-31
KR20250034521A (ko) 2025-03-11
SMT202500022T1 (it) 2025-03-12
EP4483956A3 (en) 2025-03-19
PT4483956T (pt) 2026-03-16
SI3706739T1 (sl) 2025-03-31
LT4483956T (lt) 2026-04-27
RS67956B1 (sr) 2026-04-30
US20230390252A1 (en) 2023-12-07
EP4696324A2 (en) 2026-02-18
AU2018364749A1 (en) 2020-07-02
SMT202600156T1 (it) 2026-05-12
EP4699619A3 (en) 2026-05-06
CN112292127A (zh) 2021-01-29
FI3706739T3 (fi) 2024-12-27
SG11202004332XA (en) 2020-06-29
CA3082096A1 (en) 2019-05-16
IL274532A (en) 2020-06-30
BR112020009173A2 (pt) 2020-11-03

Similar Documents

Publication Publication Date Title
US12102618B2 (en) Use of riluzole prodrugs to treat ataxias
ES2561946T3 (es) Uso de testosterona y un agonista de 5-HT1A en el tratamiento de la disfunción sexual
ES2987802T3 (es) Uso de comprimidos bucodispersables de riluzol para el tratamiento de enfermedades
JP2021527090A (ja) 老化関連神経変性の進行および/または発症を治療および/または予防するための方法および組成物
AU2017366192A1 (en) Prevention and/or treatment of chronic fatigue syndrome
JP4276779B2 (ja) 注意欠損/活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
Grosso et al. Neuroprotection beyond intraocular pressure: Game changer or quiet addiction
US20210260078A1 (en) Low dosage intranasal aminosterol dosage forms and methods of using the same
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
EP3829587A1 (en) Compositions and methods for treating brain-gut disorders
ES2310258T5 (es) Antagonistas de los receptores de adenosina A2A para tratar el síndrome de piernas inquietas o mioclono nocturno
HK40118245A (en) Troriluzole for use in the treatment of spinocerebellar ataxia 3 (sca3)
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
WO2025227053A1 (en) Nmda receptor positive allosteric modulatory compositions and methods of use thereof
Kozyolkin et al. Neurology in table:[revised]
Kumar et al. Movement disorders in children
Novick et al. 0428 EFFECTIVENESS OF ANTIPSYCHOTIC TREATMENT IN NEVER TREATED PATIENTS WITH SCHIZOPHRENIA: 36-MONTH RESULTS FROM THE SCHIZOPHRENIA OUTPATIENTS HEALTH OUTCOMES (SOHO) STUDY